Isthmus Partners LLC Has $3.16 Million Position in Ingevity Co. (NYSE:NGVT)

Isthmus Partners LLC grew its holdings in Ingevity Co. (NYSE:NGVT) by 3.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 77,484 shares of the company’s stock after purchasing an additional 2,653 shares during the period. Isthmus Partners LLC’s holdings in Ingevity were worth $3,157,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Segall Bryant & Hamill LLC raised its holdings in Ingevity by 33.5% during the third quarter. Segall Bryant & Hamill LLC now owns 1,185,415 shares of the company’s stock worth $46,231,000 after acquiring an additional 297,135 shares in the last quarter. Harvey Partners LLC bought a new stake in shares of Ingevity during the 3rd quarter worth approximately $7,878,000. State Street Corp boosted its holdings in shares of Ingevity by 14.7% in the 3rd quarter. State Street Corp now owns 1,546,957 shares of the company’s stock valued at $60,331,000 after buying an additional 198,300 shares during the last quarter. Royce & Associates LP grew its stake in shares of Ingevity by 23.3% in the third quarter. Royce & Associates LP now owns 933,677 shares of the company’s stock valued at $36,413,000 after buying an additional 176,447 shares in the last quarter. Finally, Vision One Management Partners LP bought a new position in shares of Ingevity in the third quarter valued at $4,388,000. Institutional investors own 91.59% of the company’s stock.

Ingevity Stock Performance

Shares of NGVT stock opened at $47.35 on Monday. Ingevity Co. has a 52 week low of $30.90 and a 52 week high of $56.29. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -4.00 and a beta of 1.53. The company has a 50-day simple moving average of $44.33 and a 200 day simple moving average of $41.95. The company has a debt-to-equity ratio of 6.86, a quick ratio of 1.04 and a current ratio of 1.87.

Ingevity (NYSE:NGVT) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.66. The company had revenue of $298.80 million during the quarter, compared to analysts’ expectations of $297.40 million. Ingevity had a positive return on equity of 41.44% and a negative net margin of 30.60%. On average, sell-side analysts predict that Ingevity Co. will post 4.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. BMO Capital Markets upgraded shares of Ingevity from a “market perform” rating to an “outperform” rating and increased their price target for the company from $62.00 to $65.00 in a research note on Wednesday, February 26th. StockNews.com upgraded shares of Ingevity from a “hold” rating to a “buy” rating in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.17.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.